1. Call to Order/Announcements
   - Audio-recording of Meeting
   - Introduction of Guests
   - Conflict of Interest
   - Expedited Actions Report

2. Review of Draft Minutes, August 7, 2017

3. Old Business

4. New Business

5. NIH Problem Form 09C0005-R, "Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease" - Robert Kreitman, PI

6. NIH Problem Form 17C0057-A, "A Randomized Phase II Trial of Standard of Care Alone or in Combination with Ad-CEA Vaccine and Avelumab in Patients with Previously Untreated Metastatic Colorectal Cancer" - Julius Strauss, PI

7. NIH Problem Form 15C0145-L, "Phase I/II Study of the Anti-programmed Death Ligand-1 Antibody MEDI4736 in Combination with Olaparib or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers" - Jung-Min Lee, PI

8. NIH Problem Form 16C0131-B, "Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-binding Chimeric Antigen Receptor to Patients with CD70 Expressing Cancers" - Jim Yang, PI

9. NIH Problem Form 13C0132-J, "Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC Syndrome" - Dennis Hickstein, PI

10. NIH Problem Form 15C0029-M, "Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies" - Nirali Shah, PI

11. Continuing Review 16C0011-B, "A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas" - Mark Gilbert, PI

12. Continuing Review 15C0028-A, "Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events after Participation in Pediatric Oncology Branch Clinical Trials" - Terry Fry, PI

13. Continuing Review 12C0118-K, "A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy" - Arun Rajan, PI
14. **Continuing Review** 16C0154-C, "A Phase I Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 with or without PD-1 Blockade for HPV-Associated Cancers" - Christian Hinrichs, PI

15. **Continuing Review** 17C0011-C, "Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer" - Christina Annunziata, PI

16. **Continuing Review** 94C0074-AA, "Treatment and Natural History Study of Lymphomatoid Granulomatosis" - Wyndham Wilson, PI

17. **Continuing Review** 12C0107-H, "Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: A Clinical and Correlative Study"—Dickran Kazandjian, PI


20. **Continuing Review** 02C0313-F, "Cancer Risk in Xeroderma Pigmentosum Heterozygotes" – Kenneth Kraemer, PI

21. **Response to Stips** P152242, "Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies" - Jen Kanakry, PI

22. **Response to Stips** P162946, "A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer" - Steve Rosenberg, PI

23. **Response to Stips** P173025, "A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma" - Mark Roschewski, PI
24. Amendment 16C0128-D, "A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors" - Christine Alewine, PI

25. Amendment 17C0057-A, "A Randomized Phase II trial of Standard of Care Alone or in Combination with Ad-CEA vaccine and Avelumab in Patients with Previously Untreated Metastatic Colorectal Cancer" - Julius Strauss, PI

26. Amendment 11C0221-M, "Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study" - Mark Roschewski, PI

27. Amendment 15C0145-L, "Phase I/II Study of the Anti-programmed Death Ligand-1 Antibody MEDI4736 in Combination with Olaparib or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers" - Jung-Min Lee, PI

28. Initial Review P173039, "Molecular Characterization of Viral-associated Tumors, Tumors occurring in the Setting of HIV or other Immune Disorders and Castleman Disease" - Robert Yarchoan, PI